VA to launch trial of ReWalk’s exoskeleton system

ReWalk Robotics (NSDQ:RWLK) said today that the Department of Veterans Affairs released details of a planned 4-year, national, multi-center study of ReWalk’s Personal 6.0 exoskeleton systems.

The aptly named Exoskeleton Assisted-Walking in Persons with SCI: Impact on Quality of Life study is slated to enroll 160 patients at 6 participating VA Medical Centers across California, Florida, Massachusetts, Texas and Virginia.

“This VA clinical trial is groundbreaking in both its purpose and scope, and will undoubtedly provide a wealth of quality research data to the department’s already impressive research. ReWalk is glad to provide our technology to enable this critical national study,” CEO Larry Jasinski said in a press release.

ReWalk Robotics said the VA plans to initiate the study in October this year.

In January, ReWalk Robotics said the VA awarded a delivery order to the Veterans Healthcare Supply Solutions for its Robotic Exoskeleton systems to use in the upcoming 4-year trial.

The company said it has already shipped 6 of those systems for the trial.

In December, ReWalk saw shares jump after the U.S. Department of Veterans Affairs issued a policy to evaluate, train and procure its personal exoskeleton systems for all qualifying veterans in the U.S. ReWalk stocks rose over 32% in day trading after the announcement.

ReWalk develops and produces exoskeletons designed to restore self-initiated walking for patients with spinal cord injuries. The personal system is battery-powered and features an array of sensors and motors that detect the wearer’s movement and assist in standing up, sitting down and upright walking.

The post VA to launch trial of ReWalk’s exoskeleton system appeared first on MassDevice.

from MassDevice http://ift.tt/1P6YNAi